Aside from serine/arginine-rich protein-specific kinases, by far the most abundantly studied splicing factor as a target for cancer therapy is splicing factor 3B subunit 1 (SF3B1), which is frequently mutated in cancer, especially in hematological malignancies [7]. This evidence concerns the gene SF3B1 and cancer.